Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie R Nangia

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
JCO Oncology Practice|October 7, 2021
Breast Cancer Prevention: Where Are We?Julie R Nangia, Mothaffar F Rimawi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Elacestrant and the Promise of Oral SERDsKatherine G Sanchez, Julie R Nangia, Rachel Schiff, et al.
Clinical Advances in Hematology & Oncology : H&O|January 13, 2012
Multiple myeloma with multiple extramedullary plasmacytomasJulie R Nangia, Arti A Lakhani, Jerome M Loew, et al.
Clinical Breast Cancer|March 3, 2012
Jejunal intussusception due to malignant phyllodes tumor of the breastMehmet Asim Bilen, Rodolfo Laucirica, Mothaffar F Rimawi, et al.
Expert Opinion on Biological Therapy|February 22, 2012
Denosumab for treatment of breast cancer bone metastases and beyondJulie R Nangia, Joseph D Ma, Christine M Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2018
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast DiseaseAyca Gucalp, Xi K Zhou, Elise D Cook, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
JCO Oncology Practice|October 7, 2021
Breast Cancer Prevention: Where Are We?Julie R Nangia, Mothaffar F Rimawi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Elacestrant and the Promise of Oral SERDsKatherine G Sanchez, Julie R Nangia, Rachel Schiff, et al.
Clinical Advances in Hematology & Oncology : H&O|January 13, 2012
Multiple myeloma with multiple extramedullary plasmacytomasJulie R Nangia, Arti A Lakhani, Jerome M Loew, et al.
Clinical Breast Cancer|March 3, 2012
Jejunal intussusception due to malignant phyllodes tumor of the breastMehmet Asim Bilen, Rodolfo Laucirica, Mothaffar F Rimawi, et al.
Expert Opinion on Biological Therapy|February 22, 2012
Denosumab for treatment of breast cancer bone metastases and beyondJulie R Nangia, Joseph D Ma, Christine M Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2018
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast DiseaseAyca Gucalp, Xi K Zhou, Elise D Cook, et al.
Pageof 2